Lentine Krista L, Axelrod David, Klein Christina, Simpkins Christopher, Xiao Huiling, Schnitzler Mark A, Tuttle-Newhall Janet E, Dharnidharka Vikas R, Brennan Daniel C, Segev Dorry L
1 Center for Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO. 2 Division of Abdominal Transplantation, Department of Surgery, Saint Louis University School of Medicine, St. Louis, MO. 3 Division of Abdominal Transplantation, Department of Surgery, Dartmouth Hitchcock Medical Center, Hanover, NH. 4 Transplant Nephrology, Washington University School of Medicine, St. Louis, MO. 5 Division of Abdominal Transplantation, Department of Surgery, Johns Hopkins University, Baltimore, MD. 6 Address correspondence to: Krista L. Lentine, M.D., Ph.D., Saint Louis University Center for Outcomes Research, Salus Center 4th Floor, 3545 Lafayette Ave, St. Louis, MO 63104.
Transplantation. 2014 Jul 15;98(1):54-65. doi: 10.1097/TP.0000000000000029.
Descriptions of the sequelae of ABO-incompatible (ABOi) kidney transplantation are limited to single-center reports, which may lack power to detect important effects.
We examined U.S. Renal Data System registry data to study associations of ABOi live-donor kidney transplantation with clinical complications in a national cohort. Among 14,041 Medicare-insured transplants in 2000 to 2007, 119 non-donor-A2 ABOi transplants were identified. A2-incompatible (n=35) transplants were categorized separately. Infection and hemorrhage events were identified by diagnosis codes on billing claims. Associations of ABO incompatibility with complications were assessed by multivariate Cox regression.
Recipients of ABOi transplants experienced significantly (P<0.05) higher incidence of wound infections (12.7% vs. 7.3%), pneumonia (7.6% vs. 3.8%), and urinary tract infections (UTIs) or pyelonephritis (24.5% vs. 15.3%) in the first 90 days compared with ABO-compatible recipients. In adjusted models, ABO incompatibility was associated with twice the risk of pneumonia (adjusted hazard ratio [aHR], 2.22; 95% confidence interval [CI], 1.14-4.33) and 56% higher risk of UTIs or pyelonephritis (aHR, 1.56; 95% CI, 1.05-2.30) in the first 90 posttransplantation days, and 3.5 times the relative risk of wound infections in days 91 to 365 (aHR, 3.55; 95% CI, 1.92-6.57). ABOi recipients, 19% of whom underwent pre- or peritransplant splenectomy, experienced twice the adjusted risk of early hemorrhage (aHR, 1.96; 95% CI, 1.19-3.24). A2-incompatible transplantation was associated only with early risk of UTIs or pyelonephritis.
ABOi transplantation offers patients with potential live donors an additional transplant option but with higher risks of infectious and hemorrhagic complications. Awareness of these complications may help improve protocols for the management of ABOi transplantation.
关于ABO血型不相容(ABOi)肾移植后遗症的描述仅限于单中心报告,可能缺乏检测重要影响的效力。
我们研究了美国肾脏数据系统登记数据,以探讨ABOi活体供肾移植与全国队列临床并发症之间的关联。在2000年至2007年的14,041例参加医疗保险的移植手术中,识别出119例非供体A2型ABOi移植。A2不相容(n = 35)移植单独分类。通过计费索赔中的诊断代码识别感染和出血事件。通过多变量Cox回归评估ABO血型不相容与并发症之间的关联。
与ABO相容的受者相比,ABOi移植受者在术后前90天伤口感染(12.7%对7.3%)、肺炎(7.6%对3.8%)以及尿路感染(UTI)或肾盂肾炎(24.5%对15.3%)的发生率显著更高(P < 0.05)。在调整模型中,ABO血型不相容与移植后前90天肺炎风险增加两倍(调整后风险比[aHR],2.22;95%置信区间[CI],1.14 - 4.33)以及UTI或肾盂肾炎风险增加56%(aHR,1.56;95%CI,1.05 - 2.30)相关,并且在术后91至365天伤口感染的相对风险增加3.5倍(aHR,3.55;95%CI,1.92 - 6.57)。19%的ABOi受者在移植前或移植期间接受了脾切除术,其早期出血的调整后风险增加两倍(aHR,1.96;95%CI,1.19 - 3.24)。A2不相容移植仅与UTI或肾盂肾炎的早期风险相关。
ABOi移植为有潜在活体供者的患者提供了额外的移植选择,但感染和出血并发症风险更高。了解这些并发症可能有助于改进ABOi移植的管理方案。